EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes, Transgenic Rabbits, and Patients

Lia Crotti iD, Raquel Neves iD, Federica Dagradi iD, Giulia Musu iD, Federica Giannetti iD, J Martijn Bos iD, Miriam Barbieri iD, Paolo Cerea iD, Fulvio L F Giovenzana iD, Margherita Torchio iD, Manuela Mura iD, Massimiliano Gnecchi iD und 6 weitere

Circulation · 2024

DOI: 10.1161/circulationaha.124.068959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, 2024. Verfasst von Lia Crotti und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano, IRCCS, Milan, Italy (L.C., …. Hauptthemen laut MEDLINE: Mexiletine, Myocytes, Cardiac, Long QT Syndrome, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel–mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2. METHODS: Heart rate–corrected field potential duration, a surrogate for QTc, was measured in human induced pluripotent stem cells from 2 patients with LQT2 (KCNH2-p.A561V, KCNH2-p.R366X) before and after mexiletine using a multiwell multi-electrode array system. Action potential duration at 90% repolarization (APD 90 ) was evaluated in cardiomyocytes isolated from transgenic LQT2 rabbits (KCNH2-p.G628S) at baseline and after mexiletine application. Mexiletine was given to 96 patients with LQT2. Patients were defined as responders in the presence of a QTc shortening ≥40 ms. Antiarrhythmic efficacy of mexiletine was evaluated by a Poisson regression model. RESULTS: After acute treatment with mexiletine, human induced pluripotent stem cells from both patients with LQT2 showed a significant shortening of heart rate–corrected field potential duration compared with dimethyl sulfoxide control. In cardiomyocytes isolated from LQT2 rabbits, acute mexiletine significantly shortened APD 90 by 113 ms, indicating a strong mexiletine-mediated shortening across different LQT2 model systems. Mexiletine was given to 96 patients with LQT2 either chronically (n=60) or after the acute oral drug test (n=36): 65% of the patients taking mexiletine only chronically and 75% of the patients who performed the acute oral test were responders. There was a significant correlation between basal QTc and ∆QTc during the test ( r = −0.8; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MexiletineMyocytes, CardiacLong QT SyndromeInduced Pluripotent Stem CellsAnimals, Genetically ModifiedAnimalsHumansRabbitsMaleFemaleAdultAction PotentialsAnti-Arrhythmia AgentsAdolescentMiddle AgedYoung AdultERG1 Potassium ChannelHeart RateDisease Models, AnimalChildTreatment Outcome

Stichwörter der Autor:innen

arrhythmias, cardiacdeath, sudden, cardiacgeneticslong QT syndromemexiletinepluripotent stem cellsprecision medicine

Substanzen

MexiletineAnti-Arrhythmia AgentsKCNH2 protein, humanERG1 Potassium Channel

Autor:innen und Institutionen

  • Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano, IRCCS, Milan, Italy (L.C., F.D., G.M., F.G., P.C., F.L.F.G., M.T., L.S., P.J.S.).
  • Departments of Medicine and Surgery (L.C.), University of Milano-Bicocca, Milan, Italy.
  • Department of Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory (R.N., J.M.B., M.J.A.), Mayo Clinic, Rochester, MN.
  • Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Switzerland (M.B., K.E.O.).
  • Translational Cardiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (M.M., M.G.).
  • Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Italy (M.G.).

ORCID-Profile: Lia Crotti, Raquel Neves, Federica Dagradi, Giulia Musu, Federica Giannetti, J Martijn Bos, Miriam Barbieri, Paolo Cerea, Fulvio L F Giovenzana, Margherita Torchio, Manuela Mura, Massimiliano Gnecchi, Giulio Conte, Angelo Auricchio, Luca Sala, Katja E Odening, Michael J Ackerman, Peter J Schwartz

Zitieren

APA

Crotti, L., Neves, R., Dagradi, F., Musu, G., Giannetti, F., Bos, J. M., Barbieri, M., Cerea, P., Giovenzana, F. L. F., Torchio, M., Mura, M., Gnecchi, M., Conte, G., Auricchio, A., Sala, L., Odening, K. E., Ackerman, M. J., & Schwartz, P. J. (2024). Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes, Transgenic Rabbits, and Patients. Circulation. https://doi.org/10.1161/circulationaha.124.068959

Vancouver

Crotti L, Neves R, Dagradi F, Musu G, Giannetti F, Bos JM, et al. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes, Transgenic Rabbits, and Patients. Circulation. 2024. doi:10.1161/circulationaha.124.068959

BibTeX
@article{Crotti2024,
  author = {Crotti, Lia and Neves, Raquel and Dagradi, Federica and Musu, Giulia and Giannetti, Federica and Bos, J Martijn and Barbieri, Miriam and Cerea, Paolo and Giovenzana, Fulvio L F and Torchio, Margherita and Mura, Manuela and Gnecchi, Massimiliano and Conte, Giulio and Auricchio, Angelo and Sala, Luca and Odening, Katja E and Ackerman, Michael J and Schwartz, Peter J},
  title = {Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes, Transgenic Rabbits, and Patients},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.124.068959}
}
Kostenlos starten →